Literature DB >> 27738968

EndoBarrier® in Grade I Obese Patients with Long-Standing Type 2 Diabetes: Role of Gastrointestinal Hormones in Glucose Metabolism.

Nuria Vilarrasa1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 27738968     DOI： 10.1007/s11695-016-2405-8

Source DB:  PubMed          Journal:  Obes Surg        ISSN： 0960-8923            Impact factor:   4.129


× No keyword cloud information.
  9 in total

Review 1.  Inflammatory mechanisms in obesity.

Authors:  Margaret F Gregor; Gökhan S Hotamisligil
Journal:  Annu Rev Immunol       Date:  2011       Impact factor: 28.527

2.  Six months of treatment with the endoscopic duodenal-jejunal bypass liner does not lead to decreased systemic inflammation in obese patients with type 2 diabetes.

Authors:  Charlotte de Jonge; Sander S Rensen; Hedwig M A D'Agnolo; Nicole D Bouvy; Wim A Buurman; Jan Willem M Greve
Journal:  Obes Surg       Date:  2014-02       Impact factor: 4.129

Review 3.  Adipokines in inflammation and metabolic disease.

Authors:  Noriyuki Ouchi; Jennifer L Parker; Jesse J Lugus; Kenneth Walsh
Journal:  Nat Rev Immunol       Date:  2011-01-21       Impact factor: 53.106

4.  Endoscopic duodenal-jejunal bypass liner rapidly improves type 2 diabetes.

Authors:  Charlotte de Jonge; Sander S Rensen; Froukje J Verdam; Royce P Vincent; Steve R Bloom; Wim A Buurman; Carel W le Roux; Nicolaas C Schaper; Nicole D Bouvy; Jan Willem M Greve
Journal:  Obes Surg       Date:  2013-09       Impact factor: 4.129

5.  Baseline glycated hemoglobin levels are associated with duodenal-jejunal bypass liner-induced weight loss in obese patients.

Authors:  Rodrigo Muñoz; Angelica Dominguez; Fernando Muñoz; Cesar Muñoz; Milenko Slako; Dannae Turiel; Fernando Pimentel; Alan Sharp; Alex Escalona
Journal:  Surg Endosc       Date:  2013-11-07       Impact factor: 4.584

Review 6.  The chronic inflammatory hypothesis for the morbidity associated with morbid obesity: implications and effects of weight loss.

Authors:  Daniel R Cottam; Samer G Mattar; Emma Barinas-Mitchell; George Eid; Lewis Kuller; David E Kelley; Philip R Schauer
Journal:  Obes Surg       Date:  2004-05       Impact factor: 4.129

Review 7.  Effect of the EndoBarrier Gastrointestinal Liner on obesity and type 2 diabetes: a systematic review and meta-analysis.

Authors:  U Rohde; N Hedbäck; L L Gluud; T Vilsbøll; F K Knop
Journal:  Diabetes Obes Metab       Date:  2016-01-15       Impact factor: 6.577

8.  Effect of weight loss induced by gastric bypass on proinflammatory interleukin-18, soluble tumour necrosis factor-alpha receptors, C-reactive protein and adiponectin in morbidly obese patients.

Authors:  N Vilarrasa; J Vendrell; R Sánchez-Santos; M Broch; A Megia; C Masdevall; N Gomez; J Soler; J Pujol; C Bettónica; H Aranda; J M Gómez
Journal:  Clin Endocrinol (Oxf)       Date:  2007-07-02       Impact factor: 3.478

9.  Impact of Duodenal-Jejunal Exclusion on Satiety Hormones.

Authors:  Charlotte de Jonge; Sander S Rensen; Froukje J Verdam; Royce P Vincent; Steve R Bloom; Wim A Buurman; Carel W le Roux; Nicole D Bouvy; Jan Willem M Greve
Journal:  Obes Surg       Date:  2016-03       Impact factor: 4.129
  9 in total
  2 in total

Review 1.  Endoscopic bariatrics: current therapies and future directions.

Authors:  Debashis Reja; Clark Zhang; Avik Sarkar
Journal:  Transl Gastroenterol Hepatol       Date:  2022-04-25

2.  Design of the Weight-loss Endoscopy Trial (WET): a multi-center, randomized, controlled trial comparing weight loss in endoscopically implanted duodenal-jejunal bypass liners vs. intragastric balloons vs. a sham procedure.

Authors:  Marcus Hollenbach; Christiane Prettin; Felix Gundling; Wolfgang Schepp; Jochen Seufert; Jürgen Stein; Thomas Rösch; Jens Aberle; Jürgen Feisthammel; David Petroff; Albrecht Hoffmeister
Journal:  BMC Gastroenterol       Date:  2018-07-18       Impact factor: 3.067
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.